JAHA:高血压患者全因死亡的决定因素——治疗达标时间

2018-01-19 何娜 环球医学

血压(BP)升高是心血管风险和全因死亡有力的预测因素。2017年11月,发表在《Journal of the American Heart Association》的一项研究介绍了高血压患者全因死亡的决定因素——治疗达标时间。

血压(BP)升高是心血管风险和全因死亡有力的预测因素。2017年11月,发表在《Journal of the American Heart Association》的一项研究介绍了高血压患者全因死亡的决定因素——治疗达标时间。

背景:越来越多的证据显示,收缩压降低至<140 mm Hg可以改善健康结局;然而,最佳的水平尚未确定。许多人群研究或事后分析表明,120~140 mm Hg的目标收缩压,高于和低于这个范围风险增加。研究者检测了这个假设:收缩压持续控制在120~140 mm Hg的治疗范围时间是美国退伍军人全因死亡的一个有力的决定因素。

方法和结果:对15个退伍军人管理医疗中心的689051例个体随访10年。根据血压升高记录的数字(分别为>3、1或2,以及无),将参与者分类为高血压、中度高血压和血压正常。治疗范围(120~140 mm Hg)内、高于或低于治疗范围时间按照四分位数考虑,与全因死亡相关。研究人群包括54%高血压、19.9%中度高血压和26.1%血压正常的参与者;3组相应的死亡率分别为11.5%、8%和1.9%(所有比较均P<0.0001)。血压持续在治疗范围内、高于或低于治疗范围的高血压参与者的死亡率分别为6.5%、21.9%和33.1%(所有比较均P<0.0001)。高血压参与者的死亡率从大部分持续控制四分位数的6.5%(>75%)增加至8.9%、15.6%和23.5%至较少持续控制的四分位数(分别为50%~75%、25%~50%和<25%,所有比较均P<0.0001)。

结论:在此大型队伍军人队列中,观察到治疗范围时间与全因死亡之间存在逆向和渐进的相关性。持续血压控制是全因死亡的一个有力决定因素,在每天的临床实践中应监测BP是否持续控制。

原始出处:
Doumas M, Tsioufis C, Fletcher R, et al.Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension.J Am Heart Assoc. 2017 Nov 3;6(11). pii: e007131. doi: 10.1161/JAHA.117.007131.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671010, encodeId=327116e10105f, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Wed Feb 21 13:53:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280623, encodeId=beff28062381, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jan 21 10:10:11 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267694, encodeId=97f5126e694bf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448231, encodeId=cb0014482318a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280294, encodeId=7f462802948b, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Sat Jan 20 09:52:29 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671010, encodeId=327116e10105f, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Wed Feb 21 13:53:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280623, encodeId=beff28062381, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jan 21 10:10:11 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267694, encodeId=97f5126e694bf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448231, encodeId=cb0014482318a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280294, encodeId=7f462802948b, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Sat Jan 20 09:52:29 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
    2018-01-21 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1671010, encodeId=327116e10105f, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Wed Feb 21 13:53:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280623, encodeId=beff28062381, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jan 21 10:10:11 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267694, encodeId=97f5126e694bf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448231, encodeId=cb0014482318a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280294, encodeId=7f462802948b, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Sat Jan 20 09:52:29 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
    2018-01-21 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671010, encodeId=327116e10105f, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Wed Feb 21 13:53:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280623, encodeId=beff28062381, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jan 21 10:10:11 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267694, encodeId=97f5126e694bf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448231, encodeId=cb0014482318a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280294, encodeId=7f462802948b, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Sat Jan 20 09:52:29 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671010, encodeId=327116e10105f, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Wed Feb 21 13:53:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280623, encodeId=beff28062381, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Jan 21 10:10:11 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267694, encodeId=97f5126e694bf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448231, encodeId=cb0014482318a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Jan 21 05:53:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280294, encodeId=7f462802948b, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Sat Jan 20 09:52:29 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
    2018-01-20 186****0580(小山羊)

    学习了谢谢了

    0

相关资讯

高血压患者服用阿司匹林3大注意!

阿司匹林治疗的适宜人群 2006 年 AHA/ASA 动脉粥样硬化事件一级预防指南建议,阿司匹林应长期用于 10 年心血管事件风险超过 6%~10% 的人群,以防止首次心脑血管事件的发生(Ⅰ 级推荐,A 级证据)。根据试验荟萃和指南,结合心血管疾病风险评估表,如果没有禁忌,以下 3 类高血压患者应考虑使用阿司匹林:①≥50 岁单纯高血压人群,血压控制良好,无禁忌;②<50

Endocr Rev:美国内分泌协会声明:年轻高血压患者要筛查内分泌性疾病

近期,美国内分泌学会发布了内分泌性高血压筛查科学声明,对15多种会导致高血压的内分泌性疾病的筛查给出建议,声明强调需结合临床情况进行筛查,尤其是对于年轻高血压患者,内分泌性高血压筛查至关重要。 共识指出,约15%的高血压为继发性高血压,多由肾脏或内分泌疾病引起。超过一半高血压儿童患者和近30%的年龄小于40岁的高血压青年人存在继发性病因。 原发性醛固酮增多症是引起高血压的最常见内分泌疾病。声明

高血压疫苗的是是非非

根据最新在线发表在Hypertension杂志上的研究显示,治疗高血压的潜力疫苗或有一天能发挥降低血压效果长达半年。这个研究最终可能提供一种新的高血压替代治疗方法,或许以后谁也不会需要靠吃药维持日常血压水平。 日本最新研究:DNA疫苗或降低血压长达半年 关于疫苗的研究范围最近已经从传染病扩大到慢性疾病,包括阿尔茨海默病、血脂异常、高血压。日本大阪大学的研究人员设计了一种DNA疫苗,

ACEI或ARB可减少高血压患者阿尔兹海默病风险

最新研究结果显示,廉价的降血压治疗同时能保护患者的大脑免受阿尔兹海默病的困扰。与未接受降血压治疗的患者相比,那些服用血管紧张素转换酶抑制剂(ACEI)类或血管紧张素受体拮抗剂(ARB)类药物控制血压的患者罹患阿尔兹海默病的可能性更低。该研究报告同时发表于2015年老年痴呆症协会国际会议。 穿过血脑屏障是关键 已往研究证实,如果患者中年之前出现高血压,那之后该患者罹患阿尔兹海默症的可能性

高血压患者血压升高可能损害肾脏

在进行强化降压(BP)治疗的个体中,平均血压的降低与肾功能下降的风险增加有关。研究结果将于10月31日至11月5日在位于路易斯安那州新奥尔良的Ernest N. Morial会议中心举行的2017年ASN肾脏周中发布。他们还将出现在即将出版的《美国肾脏病学会临床杂志》(CJASN)上。SPRINT试验发现,在有高心血管风险的人群中,强化的血压控制(收缩压< 120毫米汞柱)降低了早期死亡的风

Hypertension:这种心血管药物影响肥胖高血压患者运动性脂质代谢吗?

脂肪酸慢性增加会促进心肌脂毒性、血脂异常、胰岛素抵抗和2型糖尿病。相反,降低脂肪酸水平的干预可改善代谢健康。这些观察结果与心血管药物影响脂代谢作用的潜力密切相关。2018年1月,发表在《Hypertension》的一项由德国、荷兰、瑞士和印度科学家进行的多中心、随机、双盲研究,考察了沙库巴曲/缬沙坦对肥胖高血压患者运动性脂质代谢的影响。